// App-Quantinova.ai

513 : Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM).

Researchers

Presenter

  • Nancy U. Lin

Principal Investigators

  • Rebecca Sue Gelman

  • W. Jerry Younger

  • A. Gregory Sorensen

  • Elizabeth Bullitt

  • Gordon J Harris

  • Daniel Morganstern

  • Bryan P. Schneider

  • Ian E. Krop

  • Eric P. Winer

  • Jessica Sohl

  • Rachel A. Freedman

Medical Centers

  • University of North Carolina, Chapel Hill, NC

  • Siemens Healthcare North America, Malvern, PAIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, INMassachusetts General Hospital, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

  • Vascular endothelial growth factor A

Drug/Treatment

  • Bevacizumab

  • Carboplatin

  • Trastuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01004172

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved